Advanced in Heart Attack

I-chang T. Hsieh

Linkou Branch, 
Taoyuan, TNQ, TW 
Advanced in Heart Attack
Linkou Branch, 
Taoyuan, TNQ, TW 
OverviewLocationsClinical Research

Overview

I-chang Hsieh practices in Taoyuan, Taiwan. Hsieh is rated as an Advanced expert by MediFind in the treatment of Heart Attack. Their top areas of expertise are Heart Attack, Coronary Heart Disease, Acute Coronary Syndrome, Percutaneous Coronary Intervention (PCI), and Stent Placement.

Their clinical research consists of co-authoring 164 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 41 articles in the study of Heart Attack.

Locations

Linkou Branch, Taoyuan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
XIENCE 28 Global Study
XIENCE 28 Global Study
Enrollment Status: Completed
Publish Date: March 04, 2021
Intervention Type: Drug, Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

164 Total Publications

Taiwan Society of Cardiology: past, present, and future.
Taiwan Society of Cardiology: past, present, and future.
Journal: European heart journal
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsieh's expertise for a condition
ConditionClose
      View All 40 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile